Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Fluconazole 200 mg vs Diflucan in Healthy Adults
NCT04038008Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of fluconazole in fungal infection (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Observed Concentration at 120.00 hours, Area Under the Curve to Last Timepoint at 120 hours and 1 more. Started Jul 2019; status: completed.
02
Drugs
fluconazole
03
Conditions
fungal infection
Beyond the preview
Go deeper on NCT04038008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04038008.